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1. Introduction 
Traveller's diarrhoea is usually a mild gastrointestinal disorder. It is generally acute and 
short-term, but in 10 percent of all cases symptoms last for more than a week. Bacterial and 
viral agents are responsible for more than 80 percent of cases of acute traveller's diarrhoea. 
Though incriminated in only one to three percent of cases of acute traveller’s diarrhoea, 
parasites –mainly protozoa– account for about 30 percent of cases of persistent diarrhoea in 
travellers (Leder, 2009; Okhuysen, 2001). Recent acceleration and expansion of international 
travel for business, leisure, philanthropic or other purposes has contributed to an increase in 
cases of intestinal protozoal disease in the developed world (Topazian & Bia, 1994; Vassalou 
& Vassalos et al., 2010). 
2. Traveller's diarrhoea 
Since the 1950s, a decade which saw an increase in trips to exotic locales, the prospect of 
developing diarrhoea has been a major concern for foreign travellers. It is believed that 
traveller’s diarrhoea is the most common health problem of people journeying abroad for 
education, research, business, or pleasure. Traveller’s diarrhoea is classically defined as the 
passage of three or more unformed stools in a 24-hour period with or without mild 
gastrointestinal symptoms including cramps, nausea and mild fever (Steffen, 2005). More 
serious gastrointestinal symptoms, such as vomiting and dysentery with blood and/or 
mucus in the stool, are rare. Owing to the brief incubation period that ranges from hours to 
a few days, it is most likely that traveller’s diarrhoea will develop on the third or fourth day 
of the travel. A second peak is observed around the 10th day, although some digestive 
problems may occur at any time (Cailhol & Bouchaud, 2007). 
3. Aetiological agents 
Many non-infectious phenomena, such as a change in lifestyle, climate or eating habits, 
consumption of spicy foods, and psychosomatic conditions, have been incriminated as 
causes of diarrhoea in the traveller. However, traveller’s diarrhoea is generally of an 
infectious origin. Bacteria account for approximately 60 to 80 percent of all cases, whereas 
viral agents and parasites, mainly protozoa, are responsible for about 10 to 20 percent and 5 
to 10 percent of the cases, respectively (Ericsson et al., 2008). There are differences in 
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causality among travel destinations, depending on the geographical distribution of 
pathogenic organisms. Enterotoxigenic Escherichia coli, or ETEC, is a major bacterial cause of 
traveller’s diarrhoea worldwide. Several other bacteria, for instance Shigella, Campylobacter, 
Salmonella, Aeromonas, Plesiomonas, and non-cholera vibrio species, have also been involved 
(Shah, 2009). Rarely is Vibrio cholerae transmitted to western travellers. The risk of 
contracting cholera is estimated at one per 500,000 travellers to endemic areas (Synder & 
Blake, 1982). Enterotoxigenic Bacteroides fragilis, or ETBF, and Arcobacter strains including 
diarrhoeagenic Α. butzleri as well as Α. cryaerophilus, formerly considered non-pathogenic, 
have recently been shown to cause diarrhoea in those travelling to different parts of the 
Indian subcontinent and Latin America (Houf & Stephan, 2007; Jiang et al., 2010). In cruise 
ships and tourist resorts, there is high risk of acquiring viruses such as noroviruses 
(Domènech-Sánchez et al., 2009; Koo et al., 1996). Rotavirus, a common paediatric pathogen, 
has also been found in adults with traveller's diarrhoea (Anderson & Weber, 2004). Giardia is 
the most commonly encountered parasite among travellers with diarrhoea. Cryptosporidium, 
Cyclospora, Isospora, and microsporidia are emerging causes (Goodgame et al., 2005). 
Aetiological agents and their order of occurrence by different geographical regions are 
shown in Table 1. 
 
Aetiological agents Africa Latin 
America 
South Asia Southeast 
Asia 
Enterotoxigenic Escherichia 
coli 
1 1 1 5 
Enteroaggregative E. coli  2 2  
Enteropathogenic E coli 4 4  2 
Campylobacter   4 1 
Salmonella   5 3 
Shigella 3  3  
Non-cholera vibrios    4 
Norovirus 2 3   
Rotavirus 5 5   
Table 1. Traveller’s diarrhoea: aetiological agents and their order of occurrence (from 1 to 5) 
among different geographical regions (adapted from Shah et al., 2009). 
3.1 Pathogenicity 
A variety of pathogens have been shown to contribute to traveller's diarrhoea. Based on the 
pathophysiological mechanism responsible for the diarrhoea, their pathogenicity can be 
divided into non-inflammatory, enteroinvasive, and inflammatory types. However, 
irrespective of the mechanism involved, the host defence system is evaded and modulated. 
Concerning traveller’s diarrhoea of bacterial origin, the non-inflammatory diarrhoeas are 
due to enterotoxin-producing organisms, such as Vibrio cholerae and ETEC, which adhere to 
the mucosa and disrupt the absorptive and secretory functions of the enterocyte. In the case 
of viral traveller’s diarrhoea, viruses such as rotaviruses disrupt the digestive and 
absorptive functions of the enterocyte: therefore the diarrhoea caused by the rotavirus is 
classified as osmotic. Enteroinvasive organisms such as Salmonella, Shigella, Campylobacter, or 
Entamoeba histolytica produce diarrhoea by invading intestinal mucosal barriers, followed by 
the initiation of acute inflammatory reaction through activation of cytokines and other  
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Localization Enteropathogens Virulence factors Mechanisms 
Small bowel 
 
Enterotoxinogenic
E.coli (ETEC) 
Colonization factors (CFs) (adherence)
Heat-labile toxin (LT), Heat-stable toxin 
(ST) (toxins) 
Secretory 
(toxinogenic) 
Enteroaggregative
E.coli (EAEC)  
 
AAFs, dispersin (adherence) EAST1, 
Pet, Pic, ShET1 (toxins) 
Vibrio cholerae
 
ACF, TCP (adherence)
Ace, CT, RTX toxin, Zot (toxins)
Vibrio 
parahaemolyticus 
 
Vp-TDH, Vp-TRH, Vp-TDH/1 
(haemolysins) 
Rotavirus VP4 (adherence)
NSP4 (toxin) 
Osmotic 
Apoptosis of 
enterocytes 
Absorptive 
villus 
Architecture 
disruption 
Norovirus VP1-P2 domain (adherence)
Giardia spp. Variant-specific surface proteins (VSPs),
arginine deiminase
Cryptosporidium spp. Unknown
Cyclospora Unknown
Large bowel Entamoeba histolytica
 
Gal-specific adhesin , cysteine 
proteinases, amoebapores Gal/GalNAc 
lectin, amoebapore and cystein 
proteases 
Invasive 
Small bowel 
and large 
bowel 
ileocolonic 
Campylobacter spp. CadF, JlpA, LOS, MOMP, PEB1 
capsule (adherence) 
CiaB (invasion) 
CDT (toxin) 
Inflammatory 
Invasive 
Shigella spp.
 
IcP, (SopA), Pic, SigA (protease)
ShET1, ShET2, Shiga toxin (S. 
dysenteriae) (serotype 1 only) (toxin) 
Salmonella spp.
 
AgF, LpF, MisL, Pef, RatB, ShdA, SinH, 
Type 1 fimbriae (adherence) 
Vi antigen (S. enterica) (serovar typhi) 
(immune evasion)  
CdtB (S. enterica) (serovar typhi), Spv 
(toxin) 
Aeromonas hydrophila Cytotonic Alt [heat-labile] and Ast 
[heat-stable], cytotoxic Act (enterotoxin)
aerolysin (cytotoxin), hyl H 
(haemolysin). 
Yersinia enterocolitica Ail, Invasin (invasion)
Yst (toxin) 
Table 2. Traveller’s diarrhoea: localization, mechanisms and virulence factors of 
enteropathogens. 
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inflammatory mediators. In addition to enteroinvasive organisms, inflammatory diarrhoea 
can also be caused by cytotoxin-producing non-invasive bacteria, such as EAEC and 
Clostridium difficile, which adhere to the intestinal mucosa, activate cytokines and release 
inflammatory mediators (Navaneethan and Giannella, 2008).  
3.1.1 Virulence factors 
All the classical virulence factors including endotoxins, fimbriae and flagella, plasmids, 
apoptotic inducers, pathogenic islands and complete types I, II, and III secretion systems 
have been identified as being responsible for traveller’s diarrhoea. Virulence factors in 
strains of E. coli, Shigella, Salmonella, Vibrio, Campylobacter, Αeromonas, Yersinia, E. histolytica, 
Giardia, and norovirus, as well as genes encoding virulence factors in these enteropathogens 
have been analysed. These factors are listed in Table 2. Research continues into candidate 
virulence factors of Cryptosporidium spp., while virulence factors of Cyclospora are yet to be 
defined. 
4. Epidemiological data 
Each year 100 million people from industrialized countries travel to areas of high risk for 
contracting traveller’s diarrhoea, the majority of which are in the developing world. And up 
to 40 million cases of diarrhoea are reported among such travellers. Approximately 15 to 50 
percent of travellers to tropical and subtropical areas in Africa, the Caribbean and Latin 
America, or in South Asia may develop diarrhoea (Steffen, 2005). Traveller’s diarhoea can 
affect men and women equally. It is rare in travellers over the age of 55, while it is more 
frequent in children and in young adults under the age of 30 (Pitzinger et al, 1991). A 
Geosentinel study indicated that in more than 17,000 international travellers acute and 
chronic diarrhoea were the most common syndromes —at a rate of 335 diarrhoeal cases per 
1,000 returned travellers (Freedman et al., 2006). Travellers to South Central Asia are at the 
greatest risk of contracting acute diarrhoea. On the other hand, the highest rates of chronic 
diarrhoea were reported after a journey to West Africa and East Asia (Sanders et al., 2008). 
ETEC is the main causal agent of traveller’s diarrhoea in Africa, Latin America, and South 
Asia, followed by enteroaggregative E. coli, or EAEC, in Latin America and South Asia, 
whereas Campylobacter predominates in Southeast Asia (Hill & Beeching, 2010). Of the viral 
agents, noroviruses were found in mixed infections with bacteria such as ETEC in one-third 
of diarrhoea cases among those travelling to Latin America (Chapin et al., 2005). Rotaviruses 
are also frequent causes of traveller's diarrhoea in Mexico and Jamaica ( Steffen et al., 1999; 
Vollet e al., 1979,). Considering parasites, Giardia has been mostly found after travel to 
central parts of South Asia (Freedman et al., 2006). E. histolytica, like other parasites, is 
frequently encountered among travellers returning from Asia, however seldom found after 
a short stay in Mexico (Frachtman et al., 1982; Freedman et al., 2006). Study groups in Nepal, 
Haiti and Peru have shown that Cyclospora is endemic in the regions of South Asia, the 
Caribbean and Latin America, respectively (Yates, 2005). In most cases, traveller’s diarrhoea 
is quite mild, benign, and lasts for a short period of time (Hill, 2000). However, in 40 percent 
of the cases, digestive disturbances may lead to a change in travel plan with a potential for 
serious negative impact on the travel objective, for instance that of a business traveller. In 20 
to 30 percent of cases, travellers may be confined to bed for a period of time, while in some 
(<1%) hospitalization is required.  
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5. Sources and modes of transmission 
Traveller’s diarrhoea is most commonly contracted by ingesting food and/or beverage 
contaminated with faecal material of human or animal origin. Despite the popular belief 
that drinking water posed the most significant risk for traveller's diarrhoea, 
unsafe/contaminated food was shown to be the major vehicle for infection. Raw or rare 
meat, poultry and seafood, and also the fruit and vegetables eaten raw are the more likely 
vehicles to spread the pathogens. Direct contact with contaminated, unwashed hands and 
indirect transmission by non-biting flies, such as the house fly, play only secondary roles in 
the transmission of diarrhoea to the traveller. 
6. Risk factors 
There are a variety of environmental and host-related factors that can predispose travellers 
to diarrhoeal illness. These risk factors include those that are associated with travel 
destination, planning, or seasonality and those in relation with the traveller’s age, eating 
habits, or susceptibility.  
Environment has been considered to have an impact on traveller's diarrhoea. The wider 
hygiene gap between the country of origin with a higher level and that of the destination 
may put a traveller at greater risk of contracting traveller's diarrhoea. Travel destinations are 
classified into three groups according to their hygiene level. Group I includes developed 
countries such as the United States, Canada, Australia, New Zealand, Japan, and the North 
and Western European countries with high level of hygiene and consequent low risk for 
acquiring diarrhoea by travellers to those countries (at a rate less than eight percent). Group 
II consists of areas of intermediate risk (at a rate of eight to 20 percent): such as Eastern 
European countries, South Africa, tourist places in Thailand, the Caribbean, and the 
Mediterranean. Areas of low hygiene level and high risk (at a rate more than 20 percent), 
such as the most part of Asia, the Middle East, Africa, and Central and South America, 
belong to group III. Furthermore, individuals travelling to temperate regions in winter are 
less at risk: for instance, the rate for Campylobacter infection was 58 percent in autumn, while 
it was only eight percent in the wintertime (Mattila et al., 1992). A recent study indicated 
that the rate for both enteroaggregative and enteropathogenic Escherichia coli infections 
among visitors to Mexico in winter was similar to that recorded in summer, whereas the rate 
of ETEC traveller's diarrhoea increased by seven percent for each degree centigrade increase 
in weekly ambient temperature (Paredes-Paredes et al., 2011). In travellers to the Tropics, 
however, the occurrence of diarrhoea does not seem to follow a clear seasonal pattern: 
EAEC, Shigella, and rotavirus are mostly found during the dry season. And those travelling 
during the rainy season or post-moonson are at a high risk for acquiring traveller's 
diarrhoea due to ETEC or Giardia, but not viral diarrhoea. (Taylor & Echeverria, 1986). The 
effect of the El Niño/Southern Oscillation, or ENSO, climate phenomenon should also be 
considered: the rise in average annual temperatures related with ENSO event has been 
positively associated with risk of diarrhoeal disease (Lauerman, 2001; Lama et al., 2004; Sari 
Kovats et al., 2003). 
Travel plans and itineraries are also related to the possibility of exposure. Campers and 
backpackers, people who have more contact with the rural population, are at a higher risk 
than are business travellers (Piyaphanee et al., 2011). Being busy and often confined to 
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their hotel rooms, business travellers dine in their hotels. Organized travelling and 
planned itineraries may be considered safer. However, unforeseen situations may arise 
(Vassalos & Vassalou et al., 2011). For instance, travellers may end up eating food that has 
been on display for several hours or may try food from street vendors and local popular 
restaurants (Tjoa et al.,1977; Adachi, 2002). In the latter case, inadequate water supplies 
can lead to incorrect dish washing. Improper storage of food may also result from limited 
access to electricity. Recently, it has been shown that food contamination is widespread in 
developing countries despite the fact that food is cooked and served hot (Koo et al., 2008). 
Also, the individual traveller may or may not practise sound eating habits regarding 
consumption of food and/or water. Travellers visiting areas with access to clean drinking 
water and food are at lower risk for diarrhoea. In addition to all the foregoing, 
overcrowded areas such as campgrounds, military camps and cruise ships are particularly 
prone to diarrhoeal disease. 
Besides environmental factors, host-related factors, viz personal factors and host genetic 
background, may also contribute to traveller's diarrhoea risk. Traveller's diarrhoea usually 
develops at the beginning of the tour. A longer stay may, however, increase the possibility 
of the occurrence of a gastrointestinal disorder (Piyaphanee et al., 2011). Young people are 
the ones most likely to develop diarrhoeal disease because of their keenness to explore the 
local flavours. Elderly travellers are less liable to contract diarrhoea, since they are more 
cautious about what they eat and drink (Alon et al., 2010). But they are also more likely to 
suffer complications because of their immunocompromised status from having debilitating, 
underlying medical conditions, such as diabetes, renal failure or hypochlorhydria induced 
by taking antacids. Rehydration therapy is important for the very young, elderly and those 
in cardiac glycosides or diuretics (DuPont & Khan, 1994). In contrast, healthy travellers 
visiting areas of low hygienic level may only experience mild gastrointestinal symptoms. 
The development of natural immunity plays a role in the lower rates of diarrhoeal disease 
among the locals in destination countries with relatively lower levels of socio-economic 
development. Similarly, earlier travel to an area of low hygienic level would also reduce the 
possibility of acquiring traveller's diarrhoea due to the immunity acquired from previous 
exposure to pathogens prevalent in such areas (DuPont et al., 1986). That is particularly 
important for travellers with high socio-economic status, who are less likely to develop 
protective immunity in their countries of origin. 
Persons with blood type O are susceptible to developing cholera, whereas individuals with 
blood type A are more likely to get giardiasis (Harris et al., 2005; El- Ganayni et al., 1994). 
Differences in ABO, Lewis, secretor phenotypes seem to be associated with differences in 
susceptibility to infection caused by norovirus strains (Huang et al., 2002; Hutson et al., 
2002; Marionneau et al., 2005). Several single nucleotide polymorphisms, or SNPs, have been 
investigated for possible association with traveller’s diarrhoea. It was found that travellers 
with the T/T genotype in position codon 632 of the lactoferrin gene were more likely to 
develop traveller's diarrhoea (Mohamed et al., 2007). Polymorphism in the interleukin (IL)-8 
promoter appears to be associated with susceptibility to EAEC (Jiang et al., 2003), whereas 
polymorphism in IL-10 promoter is likely to be associated with traveller’s diarrohea due to 
ETEC (Flores et al., 2008). Osteoprotegerin, or OPG, is an immunoregulatory member of the 
tumour necrosis factor receptor superfamily. Polymorphism in the OPG gene has been 
found to be associated with increased susceptibility to traveller’s diarrhoea (Mohamed et al., 
2009).  
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7. Diagnostic approach 
In a returned traveller with diarrhoea, a history of events is required to be established post-
travel; a questionnaire concerning travel destination and conditions, eating habits, 
antimalarial chemoprophylaxis, onset of symptoms and other matters is suggested. In post-
travel febrile diarrhoea, the traveller should be tested for malaria, given that malarial 
gastrointestinal manifestations are quite common. Once malaria is excluded, further work 
up should include routine haematological and biochemical testing, transabdominal 
ultrasound scan, stool culture and microscopy for cells, ova and parasites. For the isolation 
of Escherichia coli, Campylobacter, Salmonella, Shigella, Aeromonas, Plesiomonas, Vibrio and 
Yersinia, standard microbiological procedures are used. ETBF culture is carried out under 
anaerobic conditions. In the past, an aetiological agent remained unidentified in about 40 
percent of such cases. Improved modern techniques have proven helpful in increasing the 
rate of identification of the cause of diarrhoea (Shah et al., 2009). The possibility of detecting 
Shigella, Salmonella or Campylobacter has increased substantially by using polymerase-chain-
reaction (PCR)-based methods. Molecular techniques are used to detect the heat-labile and 
the heat-stable toxins of ETEC, aggR gene of EAEC , ipaH and invE genes of EIEC, and the 
genes of B. fragilis toxin of ETBF. To detect noroviruses, immunochromatography and 
reverse transcriptase PCR are employed. Diagnostic approach of traveller’s diarrhoea is 
demonstrated in Figure 1. 
8. Prevention 
8.1 Hygiene measures 
Traveller’s diarrhoea is associated with inadequate sanitation and hygiene in countries 
being toured. Occurrence of traveller’s diarrhoea is also related to the hygienic standards 
practised at the food preparation level. The challenge is to avoid faecal contamination of 
food and water. Furthermore, there is a need to minimize the burden of pathogen in the 
food and/or water just before consumption (Bandres et al., 1988). It has been shown that 
consumption of cold foods stored at a temperature that allows microorganisms to grow and 
produce toxins is responsible for small clusters of sickness even in luxury hotels.  
The old adage ‘boil it, cook it, peel it, or forget it’ remains valid at the individual level. A 
traveller often wants to taste a local cuisine or to try vendor food, or a traveller may be 
forced to consume water of suspect quality. Table 3 shows a list of some foods and 
beverages that could be consumed safely during travel, and some others that are best 
avoided. Practical methods for water disinfection are: boiling for 1 min (or for 3 min at 
altitudes above 2, 000 m/6, 562 ft), or filtering through a 0.10 to 0.30 μm membrane in order 
to remove bacteria and protozoan parasites followed by chlorination or iodination to kill 
viruses. Travellers should remember to wash their hands with soap and running water or to 
use alcohol-based gels or solutions for a thorough hand-rub after going to the bathroom and 
before eating. In the case of infants, the best prevention measure is breastfeeding. 
Alternatively, infant formula should be prepared by using boiling hot water. Traveller's 
diarrhoea is also related to leisure activities such as swimming and diving in lakes or rivers, 
which are contaminated with human sewage or animal faeces. Consequently, travellers 
should choose to swim or dive in swimming-pools, which are kept properly sanitised and 
are regularly checked, even though protozoal cysts and viruses are resistant to usual levels 
of chlorination. 
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Fig. 1. Diagnostic approach and management of traveller’s diarrhoea. 
Salmonella 
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Foods and beverages that can be 
consumed 
Foods and beverages that would be better 
avoided 
Dry items such as bread, biscuits, or 
dry foods 
Syrups, jellies, jams, honey 
Any foods carefully prepared in one’s 
own apartment or hotel 
Cooked foods consumed hot 
Beverages served steaming hot 
Decontaminated water (through 
filtration, chlorination or iodination) 
Bottled water with intact seal 
apparent on opening 
Bottled carbonated drinks including 
soft drinks and beer 
Fruits peeled by the traveller 
 
Moist foods served at room temperature 
including vegetables and meats 
Underdone meat and fish 
Hot sauces on tabletop 
Seafood 
Ice-creams  
Salads 
Milk and dairy products  
Prepared foods eaten cold 
Any food served buffet-style maintained at 
room temperature 
Hamburgers not served hot or at fast food 
service restaurants with rapid turnover of 
prepared hamburgers (hamburger toppings are 
a major concern in these areas) 
Tap water even in hotels claiming filtration 
systems 
Large quantities of ice 
Non-bottled drinks  
Fruits and vegetables with intact skins: berries, 
tomatoes 
Pre-peeled fruit  
 
Table 3. Examples of foods and beverages that can be consumed and the ones better 
avoided. 
8.2 Chemoprophylaxis 
8.2.1 Non-antimicrobial agents 
Bismuth subsalicylate has been shown to provide a 65 percent protection rate in cases of 
traveller's diarrhoea, when the typical dosage of 525 mg is orally given four times daily. 
Bismuth subsalicylate cannot be used for a period more than three weeks. Bismuth 
subsalicylate should be avoided in travelling children and in travellers on anticoagulants 
owing to the activity of the salicylate ions (Diemert, 2006; Ericsson, 2005) 
8.2.2 Probiotics 
Probiotics, such as Lactobacillus rhamnosum strain GG, L. acidophilus, L. bulgaricus, and 
Saccharomyces boulardii, are live microorganisms capable of colonizing the intestine, and thus 
competing with enteric pathogenic microorganisms. These strains may secrete antimicrobial 
agents, induce the production of mucin or modulate immune response. Use of probiotics 
can be considered an alternative prophylaxis against traveller's diarrhoea, even though the 
protection provided by them is still quite low with a rate of only 47 percent (Hilton et al., 
1997; McFarland, 2007). No side effects were observed; yet in elderly or 
immunocompromised travellers and in travellers with an underlying condition, probiotcs 
should be prescribed with caution (DuPont, 2008).  
www.intechopen.com
 
Current Concepts in Colonic Disorders 
 
114 
8.2.3 Antibiotics 
Pre-travel medical consultation should make the decision regarding the need and modality 
of antibiotic prophylaxis. The doctor and traveller should first discuss the plan and duration 
of the journey. Antibiotic prophylactic is only recommended for a select group of travellers 
(DuPont & Ericsson, 1993). Such a group comprises those with immunodeficiency, including 
travellers with AIDS or neoplasia, travellers undergoing treatment with 
immunosuppressants, travellers with an underlying condition, i.e. diabetes, that could be 
worsened by the diarrhoeal illness, and those with achlorhydria or hypochlorhydria due to 
gastrectomy, administration of a H2 receptor blocker or a proton pump inhibitor.  
Antibiotic prophylaxis may also be recommended for certain important business travels of 
short duration. Situations where such a use can be justified are: travel for negotiating and 
signing important business deals, politicians gathering for summits, athletes participating in 
international meetings, speakers making presentations at international conferences, or 
students travelling for a short duration to appear in an examination or any other similar 
situation. Antibiotic prophylaxis can induce a false sense of security in a traveller who may 
consequently relax the adherence to hygiene and other precautions. This raises the 
possibility of infection by resistant organisms and worse outcomes. Hypersensitivity to the 
prescribed antibiotic can be a serious problem during travel. Vaginal candidiasis is not 
uncommon in such cases and pseudomembranous colitis due to Clostridium difficile can be a 
serious illness (DuPont et al., 2009). Antibiotic prophylaxis should be taken with caution and 
the administration should never exceed a period of two to three weeks. Although small, the 
risk of emerging resistant strains should also be taken into account, since the antibiotics 
used for traveller’s diarrhoea prophylaxis and treatment are the same. Fluoroquinolones 
provide up to 90 percent protection. The oral administration of ciprofloxacin, 500 mg once a 
day, or norfloxacin, 400 mg once a day, starts upon arrival at travel destination and 
continues for 24 to 48 hours after departure from areas of elevated risk of traveller’s 
diarrhoea. With fluoroquinolones taken as a short-term prophylaxis, the risk of side effects 
is small. Yet the emergence of resistance not just for Enterobacteriaceae strains such as 
Campylobacter spp. as found in Southeast Asia, but also for strains of Salmonella spp. and 
Shigella spp. is a major concern. Such an occurrence could reverse the progress made so far 
in the prevention and management of traveller’s diarrhoea (Kuschner et al., 1998; Lindgren 
et al., 2009; Mensa et al., 2008). This has not been a concern when using rifaximin in a dose 
of 200 mg orally twice a day. Rifaximin given orally is poorly absorbed (Koo et al., 2010). It 
offers a 58 to 77 percent protection rate and does not affect intestinal flora even after 
continuous administration for a period of two weeks (DuPont et al., 2005). Also, it can be 
used to prevent traveller’s diarrhoea in children who are at least 12 years old.  
8.3 Immunoprophylaxis and vaccines 
Although diarrhoea due to heat-labile toxin (LT) producing ETEC is more frequent in 
travellers, the development of vaccines that protect against more than one pathogenic strain 
is challenging. Today, oral, inactivated vaccine against cholera, which consists of killed 
whole cell, or WC, Vibrio cholerae and the non-toxic, recombinant cholera toxin B-subunit, or 
BS, is the only vaccine proven to fight a form of traveller’s diarrhoea. But it is only 
administered to specific travelling groups such as people involved in humanitarian aid and 
military personnel deployed overseas, if travelling to an area where they are going to be at 
unavoidable risk of exposure to cholera. Nevertheless, the amino acid sequences of cholera 
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toxin B subunit and LT toxin of ETEC share approximately 80 percent homology, thus 
implying that the WS/BS vaccine may also offer some protection against traveller’s 
diarrhoea caused by enterotoxigenic E. coli (Hill et al., 2006). Unfortunately, since the 
temporary protection provided is moderate at a rate of only seven percent, the use of 
WC/BS vaccine against cholera is therefore not routinely recommended for the majority of 
travellers (Hill et al., 2006). Transcutaneous vaccine, comprising purified LT toxin of ETEC, 
does not appear to offer either statistically significant protection against ETEC or any in 
general protection against traveller’s diarrhoea (Frech et al., 2008).  
9. Treatment 
Traveller’s diarrhoea treatment includes rehydration, diet, antisecretory agents, antimotility 
drugs, and antibiotics.  
9.1 Rehydration 
Traveller’s diarrhoea does not usually cause dehydration. If patients are otherwise healthy 
and are not dehydrated, they can drink water ad libitum. They can rehydrate by taking 
frequent, small sips of bottled/boiled water or a rehydration drink. Until diarrhoea 
subsides, patients should avoid consuming beverages with high osmolality or caffeine 
content. These drinks can aggravate diarrhoea (Ericsson et al., 2008). Fluid replacement with 
oral rehydration solution is necessary for the very young and the elderly travellers, since 
they are vulnerable to the effects of dehydration (Rose et al., 2010). Further, in potentially 
dehydrating diarrhoea cases, oral rehydration solution should be used by all age groups: 
excessive fluid loss is not a rare event among adult travellers to the developing countries, 
especially in South Asia, where enterotoxigenic E. coli is the predominant cause of traveller’s 
diarrhoea (Table 1). In an attempt to maintain a good state of hydration, vigorous treatment 
of traveller’s diarrhoea should start as soon as the diarrhoea begins (Ericsson et al., 2008; 
Rose et al., 2010). 
9.2 Diet 
Complete abstention from food is neither required nor recommended, since foods providing 
calories are necessary to facilitate renewal of mucosal cells lining the intestine (Lever & 
Soffer, 2009). Dietary restriction, on the whole, has been questioned lately except for food or 
drinks with high content of simple carbohydrates. Patients with traveller’s diarrhoea have 
been advised to restrict lactose containing foods after correcting dehydration because of 
transient lactase deficiency (Ericsson et al., 2008). But no hard evidence has yet surfaced to 
support that dietary restriction benefits those travelling to developing countries (Gottlieb & 
Heather, 2011; Huang et al., 2004). Instead, frequent small meals, incorporating well cooked 
complex carbohydrates/starch such as mashed potatoes, rice or other cereals, are being 
generally encouraged. This may not be important for a well nourished adult traveller from a 
developed country but would be an important consideration in travellers, whose nutritional 
status is borderline and may be further affected by the loss of appetite (Ericsson et al., 2008).  
9.3 Non-antimicrobial agents 
Non-antimicrobial agents can be used in cases of travellers with mild to moderate diarrhoea. 
Bismuth subsalicylate is composed of a bismuth oxide core structure with salicylate ions 
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attached to the surface. It exerts antisecretory, antimicrobial and adsorbent effects to control 
diarrhoea, even though its exact mechanism still remains unknown. It was shown that 
bismuth subsalicylate can alleviate non-specific symptoms such as nausea in patients with 
traveller’s diarrhoea (Hill & Beeching, 2011). The dosage of 525 mg is orally given every half 
hour eight times daily. In travellers with acquired immunodeficiency syndrome or with 
chronic enteric disease, bismuth absorption may occur across the damaged mucosa (DuPont 
et al., 2009b). Serious neurotoxic and nephrotoxic adverse events may be attributable to the 
use of bismuth (Bao, 2006). The highest concentrations of absorbed bismuth are found in the 
kidneys and liver (Fowler & Sexton, 2007). Bismuth subsalicylate should not be used by 
travellers with renal or hepatic impairment. Antisecretory racecadotril, 100 mg after the first 
loose stool followed by 100 mg three times daily up to seven days, which acts as a 
peripherally acting enkephlalinase inhibitor, is prescribed in patients with traveller’s 
diarrhoea. In pediatric patients, it is given as an adjunct to oral rehydration therapy. 
Antimotility agents may be good for relieving the symptoms of traveller's diarrhoea and 
used as adjuncts to antibiotic treatment. Loperamide, the most widely used antimotility 
drug, is an opioid-receptors agonist, which does not affect the central nervous system, acts 
on the opioid receptors of the myenteric plexus of the large intestine and decreases intestinal 
movements. Two capsules are recommended as the initial dose and subsequently one 
capsule is given after each unformed stool, with clinical improvement being seen within 48 
hours. Although it may trap pathogens in the intestine, loperamide may help travellers who 
cannot afford to have diarrhoea during a short-term trip of critical importance. It should not 
be given in the presence of mucus or blood in the stool with or without fever, which 
represents diarrhoea due to enteroinvasive bacteria. Loperamide may cause narcotic 
intoxication and ileus in young children and be responsible for severe constipation in the 
elderly (Galleli et al., 2010; Li et al., 2007). The use of antimotility agents by the pediatric and 
geriatric population is not always without risk and should perhaps be avoided. 
9.4 Antibiotics 
Antibiotics are used in moderate and severe traveller’s diarrhoea. Such antimicrobial agents 
are fluoroquinolones, azithromycin and rifaximin (Table 4).  
Fluoroquinolones, which are synthetic broad spectrum antibiotics, are active against 
invasive bacteria including Shigella, even though, mainly in Southeast Asia, resistance of 
Campylobacter to fluoroquinolones has emerged. In the latter case, azithromycin, which is a 
subclass of macrolide antibiotics, is recommended; it has high intracellular concentrations 
and serum-based definition of resistance does not necessarily apply to controlling the 
disease in a clinical situation. If the traveller wishes for a prompt relief from afebrile, 
gastrointestinal symptoms, loperamide can be taken in combination with one of the 
antibiotics mentioned above. Among travellers visiting Mexico, loperamide combined with 
azithromycin was shown to reduce the time from the last unformed stool when compared to 
those who were administered only azithromycin (Ericsson et al., 2007). Rifaximin, a novel 
semi-synthetic derivative of rifamycin, is active against ETEC but not against invasive 
bacteria (Taylor et al., 2008). 
9.5 Self evaluation and treatment 
Traveller’s diarrhoea usually develops shortly after arrival at the travel destination. Study 
indicates that 80 percent of patients with traveller’s diarrhoea choose to treat themselves  
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Antibiotic per osa Adults’ dosage  
(normal renal function) 
Children’s dosage  
(normal renal function)b 
Fluoroquinolones 
Norfloxacin 800 mg once or 400 mg 
b.i.d. for 1-5 days  
- 
Levofloxacin 500 mg once or 500 mg q.d. 
for 1-5 days 
- 
Ofloxacin 400 mg once or 200 mg 
b.i.d. for 1-5 days 
- 
Ciprofloxacin 750 mg once or 500 mg b.i.d 
for 1-5 days 
10-15 mg kg-1 b.i.d. for 3 days 
Macrolide 
Azithromycin 500-1000 mg c once or 
500mg q.d. for 3 days 
20 mg kg-1 q.d. for 3 days 
Rifamycin derivate 
Rifaximin 200 mg t.i.d.d - 
a Antibiotics taking should be interrupted in case of improvement 
b Children's dose should not exceed adult dose 
c 1000 mg azithromycin dose can cause nausea 
d Rifaximin should not be administered in bloody diarrhoea 
Table 4. Antibiotics dosage for moderate or severe traveller’s diarrhoea. 
irrespective of the illness being mild or more severe (Hill, 2000). For that reason, during pre-
travel consultation, travellers should be given information about the problem and 
importance of traveller’s diarrhoea and instructed on how to proceed with self-evaluation. 
Local medical help should be sought if diarrhoea lasts for more than 48 hours or in case of 
fever, blood or mucus in the stool. Otherwise, travellers could replace lost fluids and 
electrolytes and take non-antimicrobial agents in their possession. In high risk areas with 
difficult access to medical services, travellers should promptly start taking antibiotics 
(immediately after the symptoms appear, and before they get worse). The choice of 
antibiotic should be determined by the locally prevalent predominant organisms and their 
sensitivity pattern. Fluoroquinolones are usually recommended for most travel destinations 
excepting South and Southeast Asia, where azithromycin can be a better choice because of 
prevalence of fluoroquinolones-resistant Campylobacter (Table 1). For self-treatment, a single 
dose of antibiotics can be given. If there is no improvement, administration can continue for 
three days (Tribble et al., 2007). An otherwise healthy adult can take the antibiotics in 
combination with loperamide to achieve a faster improvement of diarrhoea (Ericsson et al., 
2007). 
10. Clinical course 
All patients suffering from traveller’s diarrhoea develop similar symptoms, regardless of the 
causal agent. It usually occurs within the first week of travel and resolves upon returning to 
the country of origin. The onset of traveller’s diarrhoea is usually sudden, although 
abdominal pain, anorexia, and malaise may sometimes occur before the diarrhoea begins. 
Other manifestations such as nausea and vomiting in 10 to 25 percent, mild fever in up to 30 
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percent, and blood in stool in one to 10 percent of the cases may accompany diarrhoea. 
Average duration is approximately four days. Fifty percent of patients begin to recover 
within 48 hours (Steffen et al., 1983).  
Irrespective of the aetiology, mild traveller’s diarrhoea is generally short-term: this is not the 
case with more severe attacks (Hill, 2000). It is estimated that up to 25 percent of the cases of 
traveller’s diarrhoea have more than five bowel movements in a day, and 30 to 45 percent of 
the cases may have their trip interrupted or travel plan altered for at least 12 to 24 hours 
(Steffen et al., 1987). Some patients with traveller’s diarrhoea need to seek medical help 
while travelling or upon returning to the country of origin.  
10.1 Viral gastroenteritis 
Viral gastroenteritis is an intestinal infection caused by a variety of viruses resulting in mild, 
short-term diarrhoea, with vomiting being a prominent feature. It is often clinically 
undistiguishable from bacterial acute diarrhoea. In popular travel destinations, however, 
viruses have been shown to be responsible for up to 10 percent of cases of traveller's 
diarrhoea (Apelt et al., 2010). Viruses, mostly incriminated in cases of gastroenteritis, 
include GI and GII norovirus strains (Ajami et al., 2010) and rotaviruses belonging to groups 
A and C (Peñaranda et al., 1989; Sheridan et al, 1981). Enteric adenoviruses type 40 and 41 as 
well as astroviruses, though being an important cause of acute infantile gastroenteritis, do 
not appear to be a major health problem in travellers. Viruses can be transmitted from 
person to person or through contaminated food and water. Outbreaks of norovirus 
gastroenteritis have occurred in case of travellers co-existing in relatively confined spaces, 
such as aboard cruise ships and in tourist resorts, thus being in close contact with other 
passengers and tourists, relatively (Widdowson et al., 2002; Kornylo et al., 2009) 
Noroviruses cause transient malabsorption of D-xylose and fat, while rotaviruses cause 
malabsorption of glucose through the mechanism of cAMP protein kinase (Karst et al., 2010; 
Lorrot & Vasseur, 2007). Antibiotics do not work on viral gastroenteritis. Notwithstanding 
this, non-antimicrobial agents have been found effective in the treatment of intestinal viral 
infection associated with traveller's diarrhoea. Studies have shown that mixed viral and 
bacterial infections are common in gastroenteritis (Marshall, 2002). Thus, combination 
therapy with loperamide plus antibiotic is given empirically for traveller's diarrhoea 
(Ostrosky-Zeichner & Ericsson, 2001).  
10.2 Persistent traveller’s diarrhoea 
Traveller’s diarrhoea generally resolves even without treatment. However, in 10 percent of 
cases, digestive disturbances tend to persist for more than two weeks after the onset of the 
diarrhoea. In persistent cases, the patient continues to complain of intermittent or 
continuous gastrointestinal symptoms, such as loose stools, abdominal pain, bloating or 
other non-specific symptoms. Continued intestinal infection, post-infectious mucosal 
damage, or chronic gastrointestinal functional disorder may be responsible for persistent 
traveller’s diarrhoea. In most of these cases, tests for the presence of pathogens may fail if 
sampling is delayed for a period of time after the onset (Connor, 2011).  
10.2.1 Functional disorders 
Similar to any acute inflammatory process, traveller’s diarrhoea may disrupt the brush 
border microvilli of intestinal epithelial cells where disaccharidases reside. Consequently, a 
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transient lactose intolerance may occur. Likewise, transient malabsorption of xylose, folate 
and vitamin B12 may also occur (Lindenbaum, 1965). Another post-infectious sequela is the 
development of irritable bowel syndrome, or IBS. Among sufferers, five to 10 percent are 
likely to experience non-specific gastrointestinal symptoms that are compatible with those 
of irritable bowel syndrome. Also, it has been found that 10 percent of patients with irritable 
bowel syndrome have reported travelling abroad before the onset of their symptoms 
(DuPont et al., 2010). Travellers experiencing diarrhoea during their trip were five times 
more likely than travellers without to develop post-infectious irritable bowel syndrome, or 
PI-IBS (Stermer et al., 2006). In 15 percent of travellers, traveller’s diarrhoea with serious 
symptoms can lead to post-infectious irritable bowel syndrome within a six month period 
(Okhyusen et al., 2004). Risk factors for developing post-infectious irritable bowel syndrome 
include female gender, young age, pre-existing anxiety or depression, fever or weight loss, 
and infection due to strains of Campylobacter with toxigenic properties (de la Cabada Bauche 
& DuPont, 2011). Following traveller’s diarrhoea, transient changes in intestinal motility 
should may lead to stasis and small intestinal bacterial overgrowth. This can cause 
secondary diarrhoea, and other non-specific symptoms that resemble those of irritable 
bowel syndrome (Attar et al., 1999; Tureja et al., 2008).  
10.2.2 Persistent intestinal infection 
In acute traveller’s diarrhoea, parasites account for only a small percentage of the cases. In 
persistent traveller’s diarrhoea, by contrast, intestinal protozoa are the most frequently 
encountered aetiological agents. Where travellers develop persistent diarrhoea, the most 
commonly detected enteric protozoa are Giardia, Cryptosporidium, and Entamoeba histolytica, 
followed by a small percentage of cases caused by Isospora belli and microsporidia. In returning 
traveller patients, Cyclospora cayetanensis has also been suggested to cause diarrhoea that 
continues after travel. Risk factors that are associated with contracting intestinal protozoal 
infections while travelling abroad are quite well known: longer duration of stay, and the low 
level of hygiene and socio-economic development in the country travelled (Kansouzidou et al., 
2004; Müller et al., 2001; Okhyunsen et al., 2001; Taylor et al., 1988).  
11. Intestinal protozoal diarrhoeal disease 
11.1 Giardiasis 
Giardiasis is a disease of the small intestine caused by Giardia; it has recently been included 
in the World Health Organization ‘Neglected Disease Initiative’. Clinical spectrum of Giardia 
infection may vary from asymptomatic carriage to acute and chronic diarrhoea with 
abdominal pain. G. intestinalis is a cosmopolitan flagellated protozoan of humans and other 
animals. Molecular analysis has demonstrated that Giardia isolates can be separated into at 
least eight genotypes or assemblages, namely A to H, that may show host preference (Lasek-
Nesselquist et al., 2010). Humans are mostly infected by assemblages A and B. Genomic 
difference may underlie the often distinct difference in biology and clinical manifestations 
observed between the two assemblages. This implies that Giardia assemblage A and 
assemblage B may represent two distinct species (Franzén et al., 2009). Giardia infection is 
usually transmitted by ingesting cysts found in contaminated water or food, but human-to-
human transmission has also been reported in situations of poor faecal–oral hygiene. 
Giardial encystation (when trophozoites pass through the small intestine to the colon) is 
www.intechopen.com
 
Current Concepts in Colonic Disorders 
 
120 
successful only if Giardia cysts are able to excyst after ingestion and entry into the small 
intestine (Lauwaet et al., 2007). 
11.2 Amoebiasis 
Amoebic colitis is characterized by gradual onset and symptoms present over a period of 
one to two weeks. It can thus be distinguished from bacterial dysentery. The protozoan may 
be responsible for various symptoms such as bloody diarrhoea and non-specific symptoms 
i.e. weight loss, fatigue, and abdominal pain. Also, it may cause fulminating dysentery. 
Entamoeba, whose habitat is the large intestine, is one of the most commonly detected enteric 
protozoans worldwide. It has been demonstrated that it comprises two species, E. histolytica 
and E. dispar and these cannot be morphologically differentiated from each other under the 
light microscope (Clark, 2004). However, these two species can be differentiated by using 
zymodeme patterns, monoclonal antibodies, or DNA probes (Stanley, 2003). Most recently, 
E. histolytica genome sequence has been re-annotated and re-assembled and data have been 
compared to closely related organisms (Lorenzi et al., 2010). Infection with E. histolytica is 
considered more prevalent in developing countries. It is transmitted by contaminated water 
and/or food or by the faecal-oral route. Immunocompromised persons as well as persons 
with a mental illness housed in institutional settings are at high risk for acquisition of 
amoebiasis. Entamoeba has two stages in its life cycle: active and motile trophozoite and the 
dormant cystic form. Trophozoite or the trophic form can be detected in the fresh unformed 
stool from a host. By contrast, cysts can survive outside the host, in the environment i.e. in 
water, in soils, or in food. E. histolytica is considered to be pathogenic, as opposed to the non-
pathogenic E. dispar. Since E. dispar is regarded as non-pathogenic and commensal, 
infections with E. dispar are characteristically asymptomatic. Recently, however, there have 
been reports of patients infected with E. dispar experiencing gastrointestinal symptoms 
(Fotedar et al., 2007).  
11.3 Cryptosporidiosis 
In cryptosporidiosis caused by Cryptosporidium, immunocompetent individuals experience 
acute watery diarrhoea, which is usually self-limited and accompanied by non-specific 
symptoms such as abdominal pain, nausea and fatigue. In immunocompromised hosts, 
however, clinical manifestations of cryptosporidiosis vary with the level of 
immunosuppression. For instance, in case of low levels of CD4 helper T cells, 
immunocompromised patients could have persistent diarrhoea due to cryptosporidiosis 
(Brink et al., 2002). Cryptosporidium is an apicomplexan protozoan affecting humans and 
many animals. Molecular divergence between the two C. parvum variants, which were 
shown to have differences in epidemiological and clinical features, was discovered by using 
numerous techniques. These variants are now known as C. parvum in humans and in 
animals, and C. hominis in humans (Morgan-Ryan et al., 2002). A further important advance 
in the understanding of this protozoan is the publication of the C. parvum and C. hominis 
genome sequences. However, it has been suggested that there exist differences in the genetic 
make-up of Cryptosporidium populations, indicating variation in their infectivity for humans 
(Jex et al., 2008). In addition to genotypic differences, phenotypic differences have also been 
demonstrated suggesting that additional genetic pleomorphisms within the known 
genotypes exist. Monoxenous life cycle has an asexual stage, or sporozoites, and a sexual 
stage, or oocysts, and is completed within the small intestine. Sporulated thin-walled 
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oocysts are autoinfective. Thick-walled oocysts that transmit the cryptosporidial infection 
from one host to another are resistant forms, even in chlorinated water, upon being excreted 
(Currrent and Garcia, 1991). Cryptosporidial oocysts can be excreted for weeks after the 
diarrhoea subsides. Cryptosporidium can survive in source waters for a long period of time. 
Cryptosporidial infection is transmitted by drinking contaminated water or eating 
contaminated food, and by animal-to-human or faecal-oral routes. The infective dose is low. 
In healthy, immunocompetent people, ingestion of as few as up to 30 Cryptosporidium 
oocysts can cause infection, whereas in immunocompromised patients even fewer oocysts 
are required (DuPont et al., 1995).  
11.4 Isosporiasis 
Isosporiasis, a diarrhoeal illness that is caused by Isospora belli, generally causes watery 
diarrhoea and non-specific gastrointestinal symptoms such as cramps and abdominal pain. 
In immunocompetent individuals, isosporiasis is usually transient; however, 
immunocompromised patients can experience persistent diarrhoea resembling the 
cryptosporidial diarrhoea mentioned above (Mudholar & Namey, 2010). I. belli is a coccidian 
protozoan. Although ubiquitous, I. belli is more frequently encountered in the tropical and 
subtropical countries. Humans are the sole identified reservoir for I. belli infection. 
Transmission has not yet been elucidated, even though I. belli has been suggested to be 
transmitted through contaminated water. Similar to Cryptosporidium, the I. belli life cycle has 
an asexual stage and a sexual stage in the intestine. Oocysts are immature and incapable of 
infecting the human host after excretion. The large oocysts mature outside the body and 
become sporulated and infective within a two to three day period.  
11.5 Cyclosporiasis 
Cyclosporiasis, a diarrhoeal disease caused by Cyclospora, is generally the cause of self-
limited diarrhoea accompanied by cramping, abdominal pain, nausea and other non-specific 
symptoms (Türk et al., 2004). Immunocompromised hosts, however, may experience 
prolonged diarrhoea that may become quite serious if left untreated (Türk et al., 2004). C. 
cayetanensis is a coccidian protozoan that has been associated with diarrhoea in the 
developing world. It is considered an obligatory intracellular parasite found in jejunum. 
Cyclospora reservoirs are yet to be defined, even though humans appear to be the only 
reservoir for Cyclospora, similar to I. belli (Ortega & Sanchez, 2010). It has been proposed that 
this coccidian protozoan parasite may be transmitted via contaminated water and food. In 
order to become infective, very large Cyclospora oocysts, which resemble those of 
Cryptosporidium but are roughly twice the size, need sporulation outside the body, in the 
environment: in this they are dissimilar to Cryptosporidium but similar to I. belli.  
11.6 Microsporidiosis 
Microsporidiosis is commonly found in immunosuppressed individuals (Matthis et al., 
2005). Among the numerous microsporidian species, only Enterocytozoon bieneusi and 
Encephalitozoon intestinalis are associated with intestinal infection in humans worldwide. 
Therefore, infection with E. bieneusi or E. intestinalis should be considered in cases of chronic 
diarrhoea. Microsporidia are small, obligatory, intracellular organisms that infect vertebrate 
and invertebrate hosts. Although it has been proposed that they belong to the protist group 
of archezoa, microsporidia have molecularly been re-classified from protozoa to fungi or a 
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sister group of fungi (Parfrey et al., 2006). Microsporidia have specialized polar tubes, 
asexually reproduce within the cell, and form thick-walled spores that are capable of 
surviving in the environment for a long period of time.  
11.7 Dientamoebiasis 
Recently, Dientamoeba fragilis has been regarded as a pathogenic organism (Katz & Taylor, 
2001). Most patients with dientamoebiasis report frequent unformed stools and abdominal 
pain. Mucus in the stool is sporadically observed. In about 30 percent of patients with 
dientamoebiasis, diarrhoea is persistent and may turn into the chronic form, which lasts 
more than four weeks, with abdominal pain being the predominant symptom (Stark et al., 
2005). D. fragilis is one of the smaller parasites that can live in the human large intestine. 
Unlike other intestinal protozoa that are mainly detected in the developing world, D. fragilis 
is often seen in developed countries with high levels of hygiene. Once classified as an 
amoeba, it has been demonstrated to be a close relative of the trichomonads (Johnson et al., 
2004). It is considered to be a non-flagellated trichomonad. It is worthwhile mentioning that 
D. fragilis has no apparent cyst-like forms (in this it is dissimilar to other intestinal protozoa). 
Although it still remains unclear (Barratt et al., 2011), it has been proposed that infection 
between humans occurs during the trophozoite stage. Our as-yet-unpublished results 
corroborate the possibility of intrafamily transmission (Stark et al., 2009).  
11.8 Blastocystosis 
Once thought to be a harmless inhabitant of the human gut, Blastocystis is now considered a 
potential pathogen. Immunocompromised or debilitated individuals seem more prone to 
getting a diarrhoea attributable to blastocystosis (Vassalos et al., 2008). Blastocystis sp. is a 
ubiquitous anaerobic protozoan parasite that lives in the intestine of humans, other animals 
and arthropods. Blastocystis isolates have been separated into at least 10 subtypes according 
to phylogenetic trees that have been constructed from sequences of the small subunit 
ribosomal RNA (Stensvold et al., 2009). Subtype 3 has been found to be the most common 
genotype (Tan, 2008). The protozoan is more frequently encountered in tropical and 
subtropical countries. Blastocystis is polymorphic. It has various morphological forms, 
including vacuolar, granular, amoeboid, cyst, multivacuolar and avacuolar forms, with the 
vacuolar form being the most commonly detected in stool examination. Amoeboid forms are 
predominantly seen in isolates from symptomatic patients (Tan, 2008). Blastocystis vacuolar 
forms could transit to Blastocystis cysts and vice versa. Thus, faecal–oral transmission has 
been proposed. Also, it is transmitted by contaminated water or by human-to human and 
animal-to-human routes.  
11.9 Mechanisms of diarrhoea production  
Diarrhoea caused by Giardia is mediated by increased rates of transit of small intestine 
origin as well as enhanced chloride secretion (Cotton et al., 2011). Yet the mechanisms of 
pathogenesis are poorly understood (Buret, 2007). However, host and parasite factors seem 
to contribute to the pathogenesis of Giardia infection. Increase in rates of enterocyte 
apoptosis and disruption of epithelial tight junctions lead to dysfunction in the small 
intestinal barrier resulting in activation of CD8 cytotoxic T-lymphocytes. CD8 lymphocytes 
may induce brush border microvilli injury and enterocyte malfunction that leads to 
malabsorption and maldigestion of small intestine origin (Buret, 2005). Cryptosporidium is 
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localized within a unique intracellular but extracytoplasmic niche (Tzipori & Ward, 2002). 
The coccidian parasite is found attached to brush border microvilli of epithelial cells of the 
small intestine where it can cause damage that leads to the death of enterocytes. To replace 
the damaged cells, cell division is triggered in the crypt region resulting for instance in 
hyperplasia. The absorptive function of the villar tips is impaired and chloride secretion by 
the crypt cells increases, thus leading to an overall enhancement of intestinal secretion. 
Under this proposed mechanism, Cryptosporidium-induced diarrhoea is classified as osmotic 
(Sears & Guerrant, 1994). The host immune system is likely to reduce the number of thin-
walled oocysts in an attempt to prevent autoinfection, which tends to perpetuate 
cryptosporidial infection in the host. In principle, the mechanism of diarrhoea production 
appears to follow the same pattern as seen in isosporiasis and cyclosporiasis.  
E. histolytica has been suggested to produce several potential virulence factors such as 
adhesins that enable adherence to the host cell, amoebapores that are capable of forming a 
hole in a target cell; and cysteine proteinases that can degrade extracellular matrix 
components. Intestinal inflamation, killing of mucosal cells and invasion of protozoan are 
the combined effects of these virulence factors (Padilla-Vaca & Anaya-Velázquez, 2010). 
Lysis of host neutrophils may also contribute to the cell damage. In a host-parasite interplay, 
however, it is quite possible that the virulence may reflect how much control the host is 
capable of exercising over invasion and replication of Entamoeba trophozoites (Galván-
Moroyoqui et al., 2008). Invasion of intestinal epithelium by Entamoeba trophozoites can 
result in the development of dysentery, ulcers, or an amoeboma (Suriptiastuti, 2010). 
Dysenteric syndrome is characterized by the production of small volumes of bloody, 
mucoid stools without faecal leukocytes. Amoebic 'flask-shaped' ulcers can be observed in 
sections of the gastrointestinal tract. Amoeboma is the formation of amoebic granuloma in 
the intestinal wall. If entroinvasive illness turns into chronic amoebic colitis, the disease 
mimics inflammatory bowel disease. D. fragilis is considered to cause non-invasive, 
superficial irritation of the colonic mucosa, along with an eosinophilic inflammatory 
response (Johnson et al., 2004). Blastocystis is also considered to be the cause of non-invasive 
mucosal inflammation. Our published results have shown that Blastocystis subtype 3 might 
be pathogenic, only when amoeboid forms of Blastocystis are present (Katsarou-Katsari et al, 
2008), and suggest that there are intra-specific differences within Blastocystis subtypes that 
contribute to the protozoan parasite’s pathogenicity (Vassalos et al., 2010). The host immune 
status seems to play some role on the development of blastocystosis. Immunocompromised 
patients will suffer from diarrhoeal disease as the potential pathogenic forms of Blastocystis 
thrive when host defences are weakened. Interplay with intestinal microbiota may differ 
between pathogenic and non-pathogenic forms of Blastocystis (Vassalos et al., 2008). E. 
bieneusi clusters have been found in intestinal and biliary tract cells, whereas E. intestinalis 
infects the intestinal tract and may also disseminate to the mesenteric nodes and kidney. In 
the context of host-parasite relationship, microsporidia seem to be highly sophisticated 
parasites. Not only is proteome complexity reduced in the microsporidia but also several 
eukaryotic pathways are pared down to what appears to be minimal functional units so that 
host cell manipulation can be achieved (Williams, 2009). 
11.10 Routine diagnostic arsenal 
The challenge is to identify the likely intestinal protozoal agent involved in diarrhoeal 
disease as fast and accurately as possible so that therapeutic management can start. 
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Conventional ova and parasite testing that involves light microscopic examination of stool 
samples is employed for the low cost detection of intestinal protozoal diarrhoeal disease. 
The method, however, is a labour intensive and time consuming process, and requires an 
experienced microscopist. On the other hand, antigen detection assays are considered to be 
rapid and reliable methods for detecting enteric protozoan parasites, without the need for 
skilled microscopy. Direct fluorescent antibody, enzyme-linked immunosorbent assay 
(ELISA), and rapid dipstick-like tests are the diagnostic procedures in use for antigen 
detection in diagnosis of protozoa of the intestine.  
Giardial infection can be diagnosed by identification of cysts and trophozoites in the stool; 
wet mount preparations and trichrome stained smears of stool specimens are the 
recommended procedures. Entamoeba cysts and trophozoites can also be observed by 
examining a fresh stool and by using trichrome stain. Cryptosporidium oocysts can be 
visualized with a modified acid fast stain. Similarly, identification of Isospora oocysts 
requires acid fast staining. To detect Cyclospora, however, Safranin stain is used. Cyclospora 
can also be identified in stool samples, since the protozoan is able to autofluoresce at 330 to 
380 nm under ultraviolet microscopy. Microsporidial infection can be diagnosed by 
identification of free and intracytoplasmic spores with Giemsa and modified trichrome, or 
with fluorochrome stains such as calcofluor and Uvitex 2B, stains that have an affinity for 
chitin. Morphological differences between E. bieneusi and E. intestinalis can be made out in 
small intestine biopsy specimens by electron microscopy.  
It is possible to detect Giardia by using direct immunofluorescence or ELISA. 
Cryptosporidium oocysts can be detected by using monoclonal antibody-based direct 
immunofluorescence assay or ELISA. Newly developed stool antigen detection methods, i.e. 
ELISA, capable of discriminating between E. histolytica and E. dispar may also prove 
particularly useful. For laboratory diagnosis of the enteric protozoans G. intestinalis, E. 
histolytica, and Cryptosporidium spp., diagnostic kits using immunochromatography are now 
commercially available. To detect microsporidia, free and intracytoplasmic spores can be 
examined using an indirect immunofluorescent assay with monoclonal antibodies.  
PCR-based methods are also increasingly used for the detection of intestinal protozoa in 
case of diarrhoea. Inexpensive in-house PCR protocols can be adapted to detect intestinal 
protozoa. Furthermore, the trend has been moving from the detection of a single intestinal 
protozoal agent involved in diarrhoeal disease to a multiplex approach, thus allowing 
simultaneous identification of multiple protozoan parasites in order not to loose valuable 
time (Stark et al., 2011). In our laboratory, nested multiplex PCR is routinely used to 
differentiate E. histolytica from the non-pathogenic E. dispar (Evangelopoulos et al., 2000). As 
for the differentiation of intestinal protozoa other than Entamoeba spp. at the inter- or intra-
specific level, further refinements are required in PCR-based methods. Thus, outbreaks of 
intestinal protozoal diarrhoeal disease could be readily investigated and research in 
molecular epidemiology could be made possible. Polymerase chain reaction techniques, 
such as real time PCR based on SYBR-Green fluorescence, can also be used to 
simultaneousley identify microsporidial species (Polley et al. 2011). In diarrhoeal patients 
with dientamoebiasis, highly variable intermittent shedding of D. fragilis trophozoites has 
been shown to confound diagnosis when methods such as microscopy, culture or 
conventional PCR are used to detect the protozoan. However, intermittent shedding does 
not seem to interfere with the diagnosis of dientamoebiasis in cases where real time PCR, 
which demonstrates high sensitivity, is employed. This is thus being seen as the method of 
choice (Stark et al., 2010). 
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11.11 Treatment and management  
The agents that are used for the treatment of intestinal protozoal diarrhoeal diseases are set 
out in Table 5. Concerning the treatment of giardiasis, there are several drugs including the 
5-nitroimidazole and benzimidazole derivatives, quinacrine, furazolidone, paromomycin, 
and nitazoxanide that have been proved effective and approved. Metronidazole is 
considered the antiprotozoal agent of choice for the treatment of giardial infection; however, 
decreased susceptibility to metronidazole has been reported. Therefore, albendazole can 
alternatively be administered. Combination therapy may also be used when first line drugs 
fail, nitazoxanide is not available, or co-infection with other parasites occurs (Lopez-Velez et 
al., 2010).  
Where cysts are detected in an asymptomatic Entamoeba carrier, a luminal agent, such as 
diloxanide or paromomycin, should be given to treat intraluminal infection and clear 
amoebic cysts (Stanley, 2003). In enteroinvasive disease, i.e. severe colitis due to E. 
histolytica, tissue penetrating metronidazole should be administered against invasive 
trophozoites and then a luminal amoebicide should be given to kill any remaining cysts. 
Using in vivo models, metronidazole was found to be the most effective (Becker et al., 2011). 
However, if metronidazole tolerance occurs, tinidazole may alternatively be used (Gonzales 
et al., 2009). Cryptosporidial infection is self-limited and immunocompetent hosts may only 
need to be treated supportively. In immunocompromised patients with cryptosporidiosis, 
the most commonly used agents are paromomycin, and azithromycin, which are partially 
effective. Nitazoxanide, a thiazoline compound, has been shown to be effective in 
immunocompetent individuals. However, nitazoxanide could be effective in case immune 
response is appropriate (Gargala, 2008). Consequently, in immunocompromised patients, it 
is necessary to combine treatment against cryptosporidial infection with a therapy for 
restoring immunity (Cabada & White, 2010).  
In cases of symptomatic Isospora or Cyclospora infections, trimethoprim-sulfamethoxazole, a 
sulfonamid antibiotic, is administered. In immunocompromised patients experiencing 
recurrent diarrhoeal disease, secondary prophylaxis with trimethoprim-sulfamethoxazole 
attempts to treat Isospora or Cyclospora infection, and thus prevent relapses. Nitazoxanide is 
also in use for the treatment of isosporiasis and cyclosporiasis in patients with sulfa allergy 
(Zimmer et al., 2007).  
Microsporidial infection of immunocompetent individuals is self-limited and does not 
require antiparasite treatment. Many agents have been tested in the treatment of 
microsporidia infection. However, the results have shown variable therapeutic success in 
the treatment of microsporidiosis in humans. Albendazole has been demonstrated to be 
effective against Encephalitozoon spp. such as E. intestinalis but not against Enterocytozoon 
bieneusi. Fumagillin, an irreversible inhibitor of methionine aminopeptidase-2, has been 
demonstrated to be effective for eradicating E. bieneusi, despite its side effects. In renal 
transplant recipients, fumagillin shows acceptable safety when monitoring 
immunosuppressive therapy (Champion et al., 2010).  
Currently, there is no consensus for the treatment of symptomatic dientamoebiasis (Johnson 
et al., 2004). The therapeutic agents commonly used to treat D. fragilis infection are 
metronidazole, paromomycin, newer nitroimidazole derivatives such as secnidazole and 
ornidazole, tetracycline, or a combination therapy.  
Concerning Blastocystis infections, the treating agents that are currently in use have been 
considered to be generally effective. However, decreased susceptibility to metronidazole has  
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Protozoa Drug(s) of choice Alternative drug(s) 
Giardia intestinalis Metronidazole 250 mg t.i.d. × 5 
days 
Tinidazole 2 g × 1 day 
Albendazole 400 mg q.d. × 5 days 
Quinacrine 100 mg t.i.d. × 5 days 
Paromomycin 25 – 30 mg kg-1 per 
day in 3 doses × 7 days 
Entamoeba 
histolytica 
 Asymptomatic carriers (cysts) 
Paromomycin 500 mg t.i.d. × 10 
days 
Diloxanide furoate 500 mg t.i.d. × 
10 days 
Symptomatic patients (trophozoites) 
Metronidazole 750 mg t.i.d. × 5 
days  
 or 
Tinidazole 2 g × 3 days 
 followed by 
paromomycin 500 mg t.i.d. × 10 
days 
 or 
diloxanide furoate 500 mg t.i.d. × 
10 days 
 
  
Diloxanide furoate 500 mg t.i.d. × 
10 days 
 plus 
Tetracycline 250 mg q.i.d. × 10 days 
 followed 
Chloroquine 500 mg q.i.d. × 7 days 
 
Cryptosporidium. Nitazoxanide 500 mg b.i.d. × 3- 14 
days 
Albendazole 400 mg b.i.d.x 7-14 
days  
Paromomycin 500 mg t.i.d. × 14 
days 
Isospora belli  Trimethoprim- Sulfamethoxazole 
(160mg/800mg) b.i.d. × 10days 
Ciprofloxacin 500mg b.i.d. × 7 days 
Pyrimethamine 75 mg q.d. plus 
folinic acid 10 mg q.d. × 10 days 
Cyclospora 
cayatensis  
Trimethoprim- Sulfamethoxazole 
(160mg/800mg) q.i.d. ×10days 
Nitazoxanide 500 mg b.i.d. × 3- 14 
days 
  
 
Encephalitozoon 
intestinalis 
Albendazole 400 mg b.i.d. × 14-28 
days  
  
Enterocytozoon 
bieneusi 
Albendazole 400 mg b.i.d. × 28 
days 
Fumagillin 60 mg q.d. × 14 days 
Dientamoeba fragilis Tetracycline 500 mf q.i.d. × 10 days Paromomycin 25 – 30 mg kg -1 per 
day in 3 doses × 7 days 
Metronidazole 750 mg t.i.d. × 5- 10 
days 
Blastocystis sp. Nitazoxanide 500 mg b.i.d. × 3 
days 
Metronidazole 750 mg t.i.d. × 5- 10 
days 
Trimethoprim- Sulfamethoxazole 
(160mg/800mg) b.i.d. × 7 days 
Table 5. Treatment of diarrhoeal disease due to intestinal protozoa: drugs of choice and 
alternative drugs.  
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been described. An asymptomatic Blastocystis carrier should be followed up so that a 
thorough examination could be ordered in case symptoms become evident. The use of broad 
spectrum antimicrobial should be restrained, being used only in cases of symptomatic 
Blastocystis infections. Thus, the emergence of resistant Blastocystis strains should be 
prevented (Vassalos et al., 2008). 
12. Conclusion 
Since the mid-1950s when the term ‘emporiatrics’ was coined by Waters and Kean, 
substantial progress has been made in dealing with traveller’s diarrhoea. Rather than being 
seen as an unavoidable scourge for the hapless tourist, traveller’s diarrhoea has been 
considered an illness that requires further investigation and fuller action. Currently, an 
increasing number of pathogens likely to be responsible for traveller’s diarrhoea have been 
identified (Jiang et al., 2010). Concerning classical enteropathogens, such as ETEC, the mode 
of action and regulation by host factors is known. Also, progress in prophylaxis has been 
dramatic. Old, but still good, advice for sound eating and drinking habits can now be 
coupled with drug administration.  
When taking only chemoprophylaxis, travellers may be at a lower risk of contracting 
traveller’s diarrhoea but they are not 100 percent immune from a variety of pathogens likely 
to be responsible for the illness. Travellers would be thus in error if they assume that they 
are safe and pay no attention to hygiene and sanitation rules (Wagner & Wiedermann, 
2009). There has been sustained research effort for a vaccine that would be effective against 
ETEC, the leading cause of traveller’s diarrhoea, and reduce the duration and severity of the 
symptoms. A vaccine, which combines cholera toxin subunit B with killed whole cell 
(W/rBS), is currently being assessed in clinical trials (Svennerholm, 2010). 
Concerning traveller’s diarrhoea treatment, the emergence of resistance against antibiotics 
has led to research for novel drugs or therapeutic regimens. In the United States, rifaximin 
has now been approved for the treatment of traveller’s diarrhoea attributable to non-
invasive E. coli. Rifaximin is still being evaluated for the prevention of traveller’s diarrhoea 
(Armstrong et al., 2010).  
In any such cases, prompt management is currently recommended, since it has been proved 
that induced intestinal irritation may lead to temporary or prolonged functional disorders, 
as is the case with persistent traveller’s diarrhoea that is mainly of parasitic origin (Connor, 
2011). Intestinal protozoa found in travellers complaining of persistent diarrhoea upon their 
return home from exotic destinations have practically been the sole enteric protozoa 
detected in the industrialized countries. Owing to high levels of hygiene and food safety, 
there has been a dramatic decline in infections caused by intestinal protozoa in the 
developed countries. In the last decades, however, intestinal infections due to opportunistic 
protozoa have emerged because of a marked increase in the number of 
immunocompromised individuals from a range of causes. Also, immigration from and 
adventurous travel to developing tropical countries with low hygienic level and a high 
prevalence of ubiquitous enteric protozoa have recently increased. Therefore, lately, cases of 
intestinal protozoal diarrhoeal disease have been increasing in the developed world.  
This re-emergence has rekindled interest in research on intestinal protozoa. Inter- or intra-
specific genotype differences may help explain variations in phenotypic features, various 
pathogenic mechanisms, and the presence of virulence factors of enteric protozoa. For E. 
histolytica, the parasite lifestyle was examined at the whole-genome level so that new genes 
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encoding virulence factors along with signaling pathways and processes could be identified 
(Lorenzi et al. 2010; Weedal & Neil Hall, 2011). Ongoing research on host and parasite 
factors likely to contribute to the pathogenesis of giardiasis may elucidate assemblage-
specific pathogenic mechanisms (Cotton et al., 2011). New potential drug targets have been 
discovered in an attempt to develop the next generation of antiprotozoals. Researchers test 
novel promising drugs that target unique proteins and metabolic pathways of the protozoan 
G. intestinalis (Lale et al. 2010). Others continue to attempt to develop an antiprotozoal agent 
that would be effective against the coccidian Cryptosporidium. Nitazoxanide, which was 
discovered in the 1980s, has routinely been considered an alternative treatment option in 
case of diarrhoeal disease due to Giardia, Entamoeba, Isospora and Cyclospora. In 
immunocompromised hosts, however, nitazoxanide fails to treat cryptosporidiosis unless it 
is combined with antiretroviral therapy, perhaps because of partial antiparasitic effect of 
protease inhibitors (Cabada & White, 2010). Despite its side effects, fumagillin is used for 
treating microsporidia infections. Fumagillin analogs have recently been shown to be active 
against E. histolytica (Arico-Muendel et al., 2009). Concerning dientamoebiasis and 
blastocystosis, the ambiguity that surrounds the mode of transmission of D. fragilis (Barratt 
et al., 2011) and the pathogenic stage of Blastocystis (Vassalos et al., 2008; Tan, 2008) 
complicates the management of these intestinal infections. Likewise, the role of interplay 
between host defence mechanisms and intestinal protozoan survival strategies is complex. 
Further investigation of host-parasite relationship is of critical importance in the design and 
implementation of new vaccines and candidate drugs.  
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